Catalog No. 

CS996016

Description

Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ～3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4.

Species reactivity 

Human

Applications 

Research Grade Biosimilar

Host species 

Chimeric

Expression system

Mammalian Cells

Species 

Human

Clonality 

Monoclonal

Target

CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4

Endotoxin level 

Please contact with the lab for this information.

Purity 

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P15391

Form 

Liquid

Storage buffer 

0.01M PBS, pH 7.4.

Stability and Storage 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternate Names 

SAR3419, CAS: 1269764-99-9

Note 

For research use only. Not suitable for clinical or therapeutic use.